ArticleCells2022

Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease.

Christian Büchold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.